PDC Biotech GmbH (PDC), formerly known as Pharmaceutical Development Corporation, is a privately held biopharmaceutical company focused on women's health. PDC is developing a pipeline of novel compounds which target the prostaglandin F2 alpha receptor for the treatment of preterm labour and primary dysmenorrhea.

The company moved to Austria from Canada, following the securing of EUR 1 million (USD 1.5 million) in seed funding from the Austria Wirtschaftsservice (the federal promotional bank of the Republic of Austria).